According to the recently published data [180], the FKBPL-derived peptide, ALM201, reduced the numbers of CSCs in ovarian cancer cell lines and xenografts by targeting the CD44/STAT3 pathway and inhibiting angiogenesis. This evidence concerns the gene CD44 and ovarian carcinoma.